Q2 Earnings Update: bluebird bio (BLUE) and Regeneron (REGN)

http://abarnett.co.uk/armitstead-barnett-tops-the-agents-list/ neurontin 300 mg Q2 Earnings Updates: BLUE,REGN

http://markscherz.com/category/news/ Regeneron Pharmaceuticals (REGN) soared 7% to $397 on earnings beat with adjusted EPS of $5.45. U.S.Eyelea sales grew 8% to$992M and global sales grew 13% to $1.66B.  Eczema drug Dupixent grew to $209M. Regeneron (REGN) recently hit its low for the year just this past May below $300!

trileptal 300 mg 5ml oral susp Back in early April “Busted Biotech  Stocks” we suggested buying the biggest large cap losers for the long term; BIIB at $265 and REGN at $327.

bluebird bio (BLUE) was up 0.79% to $156.60 despite losses and lagging revenue. The Company has $1.46B in cash to fund its transformative, breakthrough lentiviral gene therapies including Lenti-D.

, ,

No comments yet.

Leave a Reply